无惧挑战病变
两年临床结果依然优异



ELUVIA和其他药物支架相比，Eluvia的两年临床驱动靶病变血运重建率（CD-TLR）取得统计学显著降低



在最具挑战性的股浅动脉病变中均实现一致的两年临床驱动靶病变血运重建率

ELUVIA具有至今为止药物产品临床试验中最高的两年通畅率



In IMPERIAL RCT,CEC adjudicated all-cause mortality rare at 2 years for Eluvia was 7.1%(21/295) vs. 8.3% (12/145) for 其他药物支架.

IMPERIAL RCT CD-TLR data is intention to treat and adapted from Iida, O. VIVA 2019 presentation

1. Long Lesion TLR is as-treated as presented at FDA Panel 2019. All other TLR data sets adapted from Gray, W. LINC 2020 Presentation, are intention to treat.
2. Highest-two year primary patency based on 24-month Kaplan-Meier estimates reported for IMPERIAL, IN.PACT SFA, LEVANT II and Primary Randomizaton for 其他药物支架 RCT.
3. Intention to treat. Kaplan-Meier estimate utilizing time-to-event of clinically-driven TLR up to 730 days and Duplex Ultrasound data at 24 months. Primary patencydefined as duplex ultrasound PSVR≤2.4, in the absence of clinically-driven target lesion revascularization or baypass of the target lesion, as assessed by the DUS core lab. Adapted from Gray, W, LINC 2020 Presentation
4. In IMPERIAL RCT, Eluvia K-M Primary Patency was 83% vs. 77.1% for 其他药物支架 at 24 months, p=0.1008

ELUVIA
镍钛合金紫杉醇洗脱血管支架™

三同轴输送系统实现更精准支架释放

注册证编号：国械注进20203130358				
最小鞘管外径	输送系统长度(cm)	支架直径(mm)	产品规格型号	产品规格型号描述
6F	130cm	6mm	H74939295600410	ELUVIA 6mmX40mm 130 CM
			H74939295600610	ELUVIA 6mmX60mm 130 CM
			H74939295600810	ELUVIA 6mmX80mm 130 CM
			H74939295601010	ELUVIA 6mmX100mm 130 CM
			H74939295601210	ELUVIA 6mmX120mm 130 CM
			H74939295601510	ELUVIA 6mmX150mm 130 CM
		7mm	H74939295700410	ELUVIA 7mmX40mm 130 CM
			H74939295700610	ELUVIA 7mmX60mm 130 CM
			H74939295700810	ELUVIA 7mmX80mm 130 CM
			H74939295701010	ELUVIA 7mmX100mm 130 CM
			H74939295701210	ELUVIA 7mmX120mm 130 CM
			H74939295701510	ELUVIA 7mmX150mm 130 CM
	75cm	6mm	H74939295600470	ELUVIA 6mmX40mm 75 CM
			H74939295600670	ELUVIA 6mmX60mm 75 CM
			H74939295600870	ELUVIA 6mmX80mm 75 CM
			H74939295601070	ELUVIA 6mmX100mm 75 CM
			H74939295601270	ELUVIA 6mmX120mm 75 CM
			H74939295601570	ELUVIA 6mmX150mm 75 CM
		7mm	H74939295700470	ELUVIA 7mmX40mm 75 CM
			H74939295700670	ELUVIA 7mmX60mm 75 CM
			H74939295700870	ELUVIA 7mmX80mm 75 CM
			H74939295701070	ELUVIA 7mmX100mm 75 CM
			H74939295701270	ELUVIA 7mmX120mm 75 CM
			H74939295701570	ELUVIA 7mmX150mm 75 CM

Boston Scientific 为生命创新

生产企业：Boston Scientific Corporation 波士顿科学公司
ELUVIA OVER-THE-WIRE Drug-Eluting Vascular Stent System
镍钛合金紫杉醇洗脱血管支架
注册证编号：国械注进20203130358
禁忌内容或注意事项详见说明书
PSST-CN-XXXXXX-XXXX,Version A,2020/09/01
*沪械广审（文）第********号

波科国际医疗贸易（上海）有限公司
上海市黄浦区蒙自路763号
丰盛创建大厦31楼
电话：+86-21-6141 5959
传真：+86-21-6141 5900
邮编：200023

波士顿科学北京分公司
北京市朝阳区天泽路16号院
润世中心一期2号楼12层
电话：+86-10-8574 2988
传真：+86-10-8574 2999
邮编：100125

波士顿科学广州分公司
广州市环市东路403号
广州国际电子大厦33楼
电话：+86-20-8732 6313
传真：+86-20-8732 6015
邮编：510095

波士顿科学成都分公司
四川省成都市高新区天府大道
北段1199号2栋28楼
电话：028-63239609
邮编：610000

Boston Scientific 为生命创新

ELUVIA
镍钛合金紫杉醇洗脱血管支架™

持久缓释，无惧挑战

- 优 缓 释
- 稳 支 撑
- 高 通 畅

股浅动脉腔内治疗面临两大挑战





股浅动脉支架术后再狭窄高峰期在12个月时

Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611–617.

持久缓释，无惧挑战

ELUVIA基于INNOVA裸支架平台，
提供独特的12个月药物缓释，应对股浅动脉治疗两大挑战

革命性药物缓释技术

持续一年药物缓释，完整覆盖股浅动脉再狭窄周期



久经考验的聚合物技术搭载低剂量紫杉醇药物

ELUVIA使用与PROMUS和XIENCE冠脉支架相同聚合物，具有长期可靠安全的临床实践

1. Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2007.
2. Data on file at Boston Scientific. Represents total population of patients studied in the PROMUS and XIENCE series of clinical trials. Based on pre-clinical PK analysis. Data on file at Boston Scientific.

Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.

卓越表现：一年一期通畅率高达92.1%[1]

一期通畅率
IMPERIAL 12个月研究结果



临床驱动靶病变血运重建率
IMPERIAL 12个月研究结果



ELUVIA		其他药物支架
92.1%	VS	81.8% Kaplan-Meier Estimate (p=0.0094)

一期通畅率 12个月

*Defined as a binary endpoint determined to be patent when the duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.

1. Superiority determined in Post Hoc Superiority Analysis. 12-Month Primary Patency rate of 86.8% in the Eluvia arm (n=309) vs. 77.5% in the 其他药物支架 (n=156) are (p-value= 0.0144).